Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rashmi Chugh

Showing results (41-50 of 123) with videos related to

Pageof 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2013
A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomasAndrew J Wagner, Rashmi Chugh, Lee S Rosen, et al.
Investigational New Drugs|December 29, 2018
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumorsDavid C Smith, Rashmi Chugh, Amita Patnaik, et al.
Sarcoma|November 27, 2018
SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing TherapyEdwin Choy, Karla Ballman, James Chen, et al.
Cancer|May 4, 2024
Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 studyElizabeth T Loggers, Rashmi Chugh, Noah Federman, et al.
Cancer Research Communications|September 14, 2023
Universal Viral Screening of Patients with Newly Diagnosed Cancer in the United States: A Cost-efficiency EvaluationRiha Vaidya, Joseph M Unger, Rohit Loomba, et al.
Investigational New Drugs|August 11, 2010
Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumorsBiren Saraiya, Rashmi Chugh, Vassiliki Karantza, et al.
Sarcoma|September 20, 2019
Corrigendum to "SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy"Edwin Choy, Karla Ballman, James Chen, et al.
Sarcoma|October 2, 2013
Sporadic versus Radiation-Associated Angiosarcoma: A Comparative Clinicopathologic and Molecular Analysis of 48 CasesJennifer Hung, Susan M Hiniker, David R Lucas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2005
Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcomaRashmi Chugh, Rodney Dunn, Mark M Zalupski, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 23, 2026
Determining the feasibility of self-administered relaxing acupressure for fatigue among adolescent and young adult cancer survivorsRobert Knoerl, John Jardine, Rashmi Chugh, et al.
Pageof 13

Showing results (41-50 of 123) with videos related to

Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2013
A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomasAndrew J Wagner, Rashmi Chugh, Lee S Rosen, et al.
Investigational New Drugs|December 29, 2018
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumorsDavid C Smith, Rashmi Chugh, Amita Patnaik, et al.
Sarcoma|November 27, 2018
SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing TherapyEdwin Choy, Karla Ballman, James Chen, et al.
Cancer|May 4, 2024
Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 studyElizabeth T Loggers, Rashmi Chugh, Noah Federman, et al.
Cancer Research Communications|September 14, 2023
Universal Viral Screening of Patients with Newly Diagnosed Cancer in the United States: A Cost-efficiency EvaluationRiha Vaidya, Joseph M Unger, Rohit Loomba, et al.
Investigational New Drugs|August 11, 2010
Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumorsBiren Saraiya, Rashmi Chugh, Vassiliki Karantza, et al.
Sarcoma|September 20, 2019
Corrigendum to "SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy"Edwin Choy, Karla Ballman, James Chen, et al.
Sarcoma|October 2, 2013
Sporadic versus Radiation-Associated Angiosarcoma: A Comparative Clinicopathologic and Molecular Analysis of 48 CasesJennifer Hung, Susan M Hiniker, David R Lucas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2005
Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcomaRashmi Chugh, Rodney Dunn, Mark M Zalupski, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 23, 2026
Determining the feasibility of self-administered relaxing acupressure for fatigue among adolescent and young adult cancer survivorsRobert Knoerl, John Jardine, Rashmi Chugh, et al.
Pageof 13